Free Trial

HEALTHCARE: Glaxo (GSK: A2/A): Arexvy Age Extension - Japan

HEALTHCARE
  • Welcome news from Japan. Won't move spreads today but helps at the margins.
  • Arexvy is hoped to have over £3bn peak annual sales eventually
  • Last quarter sold £188m - which was seen as a disappointment
  • Japan has extended its use to the 50-59 age bracket from just >60 previously
  • The FDA expanded the age category in June
  • GSK's latest quarterly results saw weak take-up of the vaccine so any good news on the age extension will be welcome
73 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Welcome news from Japan. Won't move spreads today but helps at the margins.
  • Arexvy is hoped to have over £3bn peak annual sales eventually
  • Last quarter sold £188m - which was seen as a disappointment
  • Japan has extended its use to the 50-59 age bracket from just >60 previously
  • The FDA expanded the age category in June
  • GSK's latest quarterly results saw weak take-up of the vaccine so any good news on the age extension will be welcome